Traws Pharma
$1.64
100
-$0.02-1.2% Thursday 20:00
Statistics
Day High
1.72
Day Low
1.5
52W High
3.27
52W Low
0.97
Volume
85,820
Avg. Volume
192,070
Mkt Cap
13.11M
P/E Ratio
0.62
Dividend Yield
-
Dividend
-
Upcoming
Earnings
14MayExpected
Expected EPS
-0.78
Actual EPS
N/A
Financials
-73,682.74%Profit Margin
Unprofitable452,000Revenue
-333.05MNet Income
Analyst Ratings
$8.00Average Price Target
The highest estimate is 8.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TRAW. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Pfizer
PFE
Mkt Cap140.15B
Merck
MRK
Mkt Cap214.76B
Novartis
NVS
Mkt Cap237.61B
Abbvie
ABBV
Mkt Cap385.18B
Astrazeneca
AZN
Mkt Cap256.58B
Lilly(Eli) &
LLY
Mkt Cap772.28B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
About
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Show more...
CEO
Dr. Victor Moyo M.D.
Employees
6
Country
US
ISIN
US68232V8845
Listings
0 Comments
Share your thoughts
FAQ
What is Traws Pharma stock price today?▼
The current price of TRAW is $1.64 USD — it has decreased by -1.2% in the past 24 hours. Watch Traws Pharma stock price performance more closely on the chart.
What is Traws Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Traws Pharma stocks are traded under the ticker TRAW.
Is Traws Pharma stock price growing?▼
TRAW stock has fallen by -6.82% compared to the previous week, the month change is a +2.5% rise, over the last year Traws Pharma has showed a -16.33% decrease.
What is Traws Pharma market cap?▼
Today Traws Pharma has the market capitalization of 13.11M
When is the next Traws Pharma earnings date?▼
Traws Pharma is going to release the next earnings report on May 14, 2026.
What were Traws Pharma earnings last quarter?▼
TRAW earnings for the last quarter are -0.34 USD per share, whereas the estimation was -9.16 USD resulting in a +96.29% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Traws Pharma revenue for the last year?▼
Traws Pharma revenue for the last year amounts to 452,000 USD.
What is Traws Pharma net income for the last year?▼
TRAW net income for the last year is -333.05M USD.
How many employees does Traws Pharma have?▼
As of April 05, 2026, the company has 6 employees.
In which sector is Traws Pharma located?▼
Traws Pharma operates in the Health Care sector.
When did Traws Pharma complete a stock split?▼
The last stock split for Traws Pharma was on September 23, 2024 with a ratio of 1:25.
Where is Traws Pharma headquartered?▼
Traws Pharma is headquartered in Newtown, US.